Rahul S. Bhansali

Hematology
3400 Spruce St
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

LDB1-dependent enhancer connectivity defines T-cell leukemia identities and masks metabolic vulnerabilities.

LDB1-dependent enhancer connectivity defines T-cell leukemia identities and masks metabolic vulnerabilities.

Journal: bioRxiv : the preprint server for biology
Published: July 10, 2026

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Journal: Haematologica
Published: March 06, 2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal
Published: December 12, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances
Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances
Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances
Published: September 24, 2025

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Journal: Cancers
Published: May 28, 2025

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Journal: Blood advances
Published: May 09, 2025

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Journal: Blood advances
Published: April 24, 2025

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Journal: Blood cancer journal
Published: September 03, 2024

DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.

DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.

Journal: Leukemia
Published: July 19, 2024

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.

Journal: Blood
Published: February 12, 2024
Showing 1-12 of 29

Last Updated: 09/26/2026